Online inquiry

IVTScrip™ mRNA-Anti-CD3E&TNFRSF17, JNJ-64007957(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9652MR)

This product GTTS-WQ9652MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets CD3E&TNFRSF17 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Homo sapiens; Chimeric
RefSeq NM_000733.4; NM_001192.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 608
UniProt ID P07766; Q02223
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&TNFRSF17, JNJ-64007957(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ9652MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3146MR IVTScrip™ mRNA-Anti-C3&C4, APT070(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA APT070
GTTS-WQ12945MR IVTScrip™ mRNA-Anti-MUC1, PankoMab(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA PankoMab
GTTS-WQ4173MR IVTScrip™ mRNA-Anti-LAG3, BI-754111(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BI-754111
GTTS-WQ14143MR IVTScrip™ mRNA-Anti-PCSK9, aPCSK927(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA aPCSK927
GTTS-WQ14979MR IVTScrip™ mRNA-Anti-IL17A, SHR-1314(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA SHR-1314
GTTS-WQ3443MR IVTScrip™ mRNA-Anti-S, AZD8895(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AZD8895
GTTS-WQ11955MR IVTScrip™ mRNA-Anti-LTA, MLTA3698A(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MLTA3698A
GTTS-WQ831MR IVTScrip™ mRNA-Anti-CD276, ABBV-155(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABBV-155
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW